New antibody drug aims to save Insulin-Making cells in type 1 diabetes
NCT ID NCT07670650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tests SAB-142, an antibody that targets immune cells, in 108 people aged 5 to 40 with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin over 12 months. Participants receive either the drug or a placebo alongside standard diabetes care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAB-142 (a lab-made antibody that targets immune cells)
- What this could lead to
- If it works, SAB-142 could help people with type 1 diabetes keep making some of their own insulin for longer, reducing the need for injected insulin.
- What could go wrong
- This is an early Phase 3 trial with only 108 participants, so results may not apply to everyone. The drug may not preserve insulin production better than placebo, and there are risks from the immune-suppressing effects of the antibody.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barbara Davis Center for Diabetes
Aurora, Colorado, 80045, United States
-
IUH - Riley Hospital for Children - Riley Outpatient Center - Pediatric Diabetes & Endocrinology
Indianapolis, Indiana, 46202, United States
-
University of California San Francisco Benioff Children's Hospital
San Francisco, California, 94158, United States
-
University of Florida
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Open-Source insulin systems match commercial ones without meal announcements?
- A glucose Monitor's second chance: can it tame type 1 diabetes in High-Risk teens?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Immune cell study may unlock kidney protection in type 1 diabetes
- Could an arthritis drug stop type 1 diabetes before it starts?